WO2010121559A1 - 新型exendin变体及其缀合物 - Google Patents
新型exendin变体及其缀合物 Download PDFInfo
- Publication number
- WO2010121559A1 WO2010121559A1 PCT/CN2010/072094 CN2010072094W WO2010121559A1 WO 2010121559 A1 WO2010121559 A1 WO 2010121559A1 CN 2010072094 W CN2010072094 W CN 2010072094W WO 2010121559 A1 WO2010121559 A1 WO 2010121559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- exendin
- ser
- glu
- gly
- kda
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 claims abstract description 77
- 239000008280 blood Substances 0.000 claims abstract description 77
- 229920000642 polymer Polymers 0.000 claims abstract description 61
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 53
- 239000008103 glucose Substances 0.000 claims abstract description 52
- 230000037396 body weight Effects 0.000 claims abstract description 41
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 169
- 239000002202 Polyethylene glycol Substances 0.000 claims description 163
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 239000000243 solution Substances 0.000 claims description 78
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 57
- 235000018417 cysteine Nutrition 0.000 claims description 57
- 230000000694 effects Effects 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 47
- 108010011459 Exenatide Proteins 0.000 claims description 46
- 229960001519 exenatide Drugs 0.000 claims description 45
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 42
- 235000001014 amino acid Nutrition 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 41
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 33
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 28
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- -1 polyethylene Polymers 0.000 claims description 23
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 125000003827 glycol group Chemical group 0.000 claims description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000003568 thioethers Chemical class 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 239000012931 lyophilized formulation Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 230000001268 conjugating effect Effects 0.000 abstract description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 76
- LFIXCKKOMUUOPU-UHFFFAOYSA-N n-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2h-quinolin-3-yl]-n-[(1-methylsulfonylpiperidin-4-yl)methyl]pyridine-2-sulfonamide Chemical compound CN1C=NC=C1CN1C2=CC=C(C#N)C=C2CC(N(CC2CCN(CC2)S(C)(=O)=O)S(=O)(=O)C=2N=CC=CC=2)C1 LFIXCKKOMUUOPU-UHFFFAOYSA-N 0.000 description 73
- 238000004458 analytical method Methods 0.000 description 49
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 43
- 239000007974 sodium acetate buffer Substances 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 230000004048 modification Effects 0.000 description 30
- 238000012986 modification Methods 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 29
- 239000000872 buffer Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- 238000004128 high performance liquid chromatography Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 230000006320 pegylation Effects 0.000 description 22
- 241000700159 Rattus Species 0.000 description 21
- 206010047700 Vomiting Diseases 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 230000037406 food intake Effects 0.000 description 19
- 235000012631 food intake Nutrition 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 230000008673 vomiting Effects 0.000 description 19
- UZYPMTAFRMVAIU-UHFFFAOYSA-N n-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2h-quinolin-3-yl]-n-[[1-(2-methylprop-2-enoyl)piperidin-4-yl]methyl]pyridine-2-sulfonamide Chemical compound C1CN(C(=O)C(=C)C)CCC1CN(S(=O)(=O)C=1N=CC=CC=1)C1CC2=CC(C#N)=CC=C2N(CC=2N(C=NC=2)C)C1 UZYPMTAFRMVAIU-UHFFFAOYSA-N 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 239000004317 sodium nitrate Substances 0.000 description 17
- 235000010344 sodium nitrate Nutrition 0.000 description 17
- GRASDRDYOYNQFY-UHFFFAOYSA-N n-[[1-(benzenesulfonyl)piperidin-4-yl]methyl]-n-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2h-quinolin-3-yl]pyridine-2-sulfonamide Chemical compound CN1C=NC=C1CN1C2=CC=C(C#N)C=C2CC(N(CC2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)S(=O)(=O)C=2N=CC=CC=2)C1 GRASDRDYOYNQFY-UHFFFAOYSA-N 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 206010020751 Hypersensitivity Diseases 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 241000700198 Cavia Species 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 description 10
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 9
- 208000030961 allergic reaction Diseases 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000001509 sodium citrate Substances 0.000 description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 238000012449 Kunming mouse Methods 0.000 description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 238000004255 ion exchange chromatography Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000008093 supporting effect Effects 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 208000013016 Hypoglycemia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000004115 Sodium Silicate Substances 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 7
- 229910052911 sodium silicate Inorganic materials 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- 230000001550 time effect Effects 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 108010015174 exendin 3 Proteins 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000003191 femoral vein Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229920000547 conjugated polymer Polymers 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 4
- 241000272201 Columbiformes Species 0.000 description 4
- 238000011537 Coomassie blue staining Methods 0.000 description 4
- 102000051325 Glucagon Human genes 0.000 description 4
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 101710176384 Peptide 1 Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000000538 analytical sample Substances 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 231100000272 reduced body weight Toxicity 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 2
- 208000008279 Dumping Syndrome Diseases 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000032395 Post gastric surgery syndrome Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- GBFLZEXEOZUWRN-UHFFFAOYSA-N carbocisteine Chemical compound OC(=O)C(N)CSCC(O)=O GBFLZEXEOZUWRN-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- YSVMULOOWPBERR-AKGZTFGVSA-N (2s)-2,6-diamino-3-hydroxyhexanoic acid Chemical compound NCCCC(O)[C@H](N)C(O)=O YSVMULOOWPBERR-AKGZTFGVSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- KCKPRRSVCFWDPX-UHFFFAOYSA-N 2-[methyl(pentyl)amino]acetic acid Chemical compound CCCCCN(C)CC(O)=O KCKPRRSVCFWDPX-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001444 polymaleic acid Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000003820 β-cell dysfunction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel Exendin variants and conjugates thereof conjugated to polymers, pharmaceutical compositions containing them and their use in lowering blood glucose, especially in the treatment of diabetes, particularly type II diabetes.
- the invention also relates to the use of an Exendin conjugate for reducing body weight.
- diabetes has become a major health care issue in countries around the world.
- the incidence of diabetes is rising sharply in both developed and developing countries.
- type II diabetes accounts for more than 90% of diabetic patients.
- Type II diabetes is characterized by insulin secretion or dysfunction and ⁇ -cell dysfunction, resulting in disorder of fat, carbohydrate and protein metabolism, resulting in chronic hyperglycemia, which eventually leads to complications of various microvasculature, large blood vessels and various organs.
- insulin-promoting substances such as sulfonylureas, meglitinides, dipeptidyl peptidase inhibitors, GLP-1 analogues
- non-insulin-promoting drugs such as insulin, ⁇ -glucosidase inhibitors, biguanides, thiazolidinediones, insulin analogues, etc.
- the traditional use of traditional diabetes drugs in clinical practice is incapable of treating patients with type 2 diabetes. It cannot suppress the progressive deterioration of pancreatic ⁇ -cells, and can not reduce the level of glycated hemoglobin (HbAlc) in the blood, nor can it prevent diabetes. Complications such as heart disease, kidney failure Exhausted, and are accompanied by varying degrees of toxic side effects. Therefore, it is necessary to study new treatment drugs for type II diabetes.
- HbAlc glycated hemoglobin
- GLP-1 gutagon-like peptide-1
- GLP-1 has the following functions: Glucose-dependent action on islet ⁇ -cells, promotes transcription of insulin genes, increases insulin biosynthesis and secretion; stimulates proliferation of ⁇ -cells And differentiation, inhibit ⁇ -cell apoptosis to increase the number of islet ⁇ -cells; inhibit glucagon secretion; increase peripheral cell insulin receptor sensitivity; reduce HbAlc; suppress appetite and food intake; delay gastric contents emptying ( Diabetic Med, 18, 144-149, 2001; Diabetes, 51, 1443-1452, 2002; Diabetologia, 45, 1263-1273, 2002; Diabetes, 50, 525-529, 2001; Diabetes, 50, 725, 2001; Diabetes , 52, 365-371, 2003; Recent Prog.
- GLP-1 is easily degraded by dipeptidyl peptidase (DPPlV) in vivo. With a half-life of less than 2 minutes, it can hardly be an effective anti-diabetic drug.
- DPPlV dipeptidyl peptidase
- Exendin-4 is a polypeptide found in the salivary secretions of the poison lizards (inland reptiles of Arizona and Northern Mexico) (J. Biol. Chem, 265, 20259-20262, 1990; J. Biol. Chem, 267 , 7402-7405, 1992 ), with high homology (53%) with glucagon-like peptide-1 (GLP-1 (7-36)).
- Exendin-4 can also bind to the GLP-1 receptor and pharmacologically exhibit similar agonistic effects as GLP-1, such as: increased insulin synthesis and glucose-dependent insulin secretion; stimulation of beta cell proliferation And regeneration, inhibit ⁇ -cell apoptosis and increase the number of ⁇ -cells; inhibit glucagon secretion; inhibit hepatic glucose production, but not cause severe hypoglycemia; inhibit post-prandial gastrointestinal motility and secretion function; Appetite, reduce food intake; protects nerve cells (Nat. Biotech, 23, 857-861, 2005; J. Biol. Chem., 266, 2897-2902, 1991; J. Biol.
- Exendin-4 promotes insulin secretion and inhibits postprandial glucagon secretion. It has blood glucose dependence, is superior to the currently used sulfonylurea hypoglycemic agents, is not prone to hypoglycemia, and can greatly reduce the number of blood glucose monitoring, and can Reduce weight.
- Exendin-4 preparation (Exenatide, trade name: Byetta), which was developed twice a day by Amylin and Eli Lilly, was launched in the US and Europe in 2005 and 2006 (US Patents 5,424,286 6,858,576, 6,872,700, 6,902,744, 6,956,026, 7,297,761 ) make this class of drugs widely used in the field of diabetes and obesity treatment worldwide.
- Exenatide needs to be used twice a day, which imposes a heavy burden on the patient's body, mind and economy, and limits the patient's medication compliance. Therefore, structural modification of Exendin-4 and development of new dosage forms to prolong its plasma cycle and increase its systemic drug exposure are hot topics in current anti-diabetic drug research.
- Polymer modification technology is a powerful modification technology developed in the 1970s, especially PEGylation technology.
- the technology combines polyethylene glycol (PEG) with protein drugs to modify the surface of the protein.
- PEG polyethylene glycol
- the coupled PEG chain produces a steric hindrance effect on the surface of the modified protein molecule, which reduces the hydrolysis of the protein by proteolytic enzymes in the blood, thereby effectively prolonging the residence time in the circulatory system, resulting in the drug plasma cycle. Prolonged and systemic drug exposure increases and improves efficacy.
- PEGylation technology has been developed to the second generation - site specific PEGylation.
- the site-specific PEGylation technology can specifically modify a specific amino acid of a protein drug, thereby avoiding random modification of blindness. This will not only affect the active central structure of the protein polypeptide, but also selectively interfere with certain antigenic sites, thereby reducing the biological activity caused by non-site PEGylation. Disadvantages such as low uniformity.
- the invention provides an Exendin variant having GLP-1 receptor agonist activity, wherein one or more amino acid residues are substituted with a cysteine as compared to the wild-type Exendin sequence.
- the Exendin variant further has one or more further amino acid deletions, additions and/or substitutions as compared to the wild-type Exendin sequence, wherein the added or replaced amino acid residues may be natural or unnatural. Amino acid or amino acid analog.
- the Exendin variant has a wild type
- the Exendin variant has a cysteine substitution at least at the C-terminus of the variant. Still preferably, the Exendin variant has a cysteine substitution at the last amino acid at the C-terminus. Furthermore, the Exendin variant preferably has a cysteine substitution at least at one or more of the following positions: with the 20th Arg (arginine), 25th Trp (tryptophan) in Exendin-4 or Exendin-3 The position corresponding to the 35-position Ala (alanine) and the 39th Ser (serine).
- the invention provides an Exendin variant conjugate conjugated to one or more natural or synthetic polymeric groups, preferably a physiologically acceptable polymer group, in the Exendin variant A group, such as a polyalkylene glycol group, more specifically a polyethylene glycol group.
- a physiologically acceptable polymer group such as a polyalkylene glycol group, more specifically a polyethylene glycol group.
- the polymer groups may be the same or different.
- the polymeric group is conjugated to the Exendin variant by one or more cysteine residues.
- the polymeric group is conjugated to the Exendin variant with a thioether linkage.
- the biological activity of the conjugated biomolecule will be an index as the molecular weight of the conjugated group (eg, from 4 kDa) increases.
- Rationality of potent, long-lasting form of interferon A 40 kDa branched polyethylene gly col-conjugated interferon a -2a for the treatment of hepatitis C. Bioconjugate Chem 2001; 12: 195-202; Bowen et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein.
- the present inventors have unexpectedly discovered that in the Exendin variant conjugates of the invention, even if the molecular weight of the polymer group is increased to 30 kDa, the conjugation is compared to the unconjugated Exendin variant.
- the molecule still retains most of the GLP-1 receptor agonist activity.
- the Exendin variant conjugates of the invention still retain comparable GLP-1 receptor agonist activity.
- the GLP-1 receptor agonist of the Exendin variant conjugate is compared to the unconjugated Exendin variant. The activity is basically unchanged.
- the invention provides an Exendin variant conjugate having an extended biological half-life and/or plasma half-life and significant GLP-1 receptor agonist activity.
- the polymer is a polyalkylene glycol, including, for example, polyethylene glycol, polypropylene glycol, and the like.
- the one or more polymer groups may have any suitable molecular weight, for example, the molecular weight may range from 2 kDa to 50 kDa, preferably from 5 kDa to 30 kDa, still preferably from 20 kDa to 30 kDa, such as 21 kDa, 22 kDa, 23 kDa, 24 kDa, 25 kDa, 26 kDa, 27 kDa, 28 kDa, 29 kDa and 30 kDa and any value between the above molecular weight values.
- the Exendin variant conjugate can also be conjugated to one or more of the same or different polymers described above at one or more other amino acid residue positions.
- the one or more additional amino acid residue positions may each be located at the N-terminus, C-terminus and/or any intermediate position of the Exendin variant.
- the conjugated polymer may be of any suitable configuration including, for example, a single arm, a double arm, a multiple arm, and/or a bifurcated, wherein each arm or bifurcation may be the same or different.
- the invention also provides a process for the preparation of the above Exendin variant conjugate comprising contacting the Exendin variant with the polymer, preferably wherein the polymer carries an activating group or upon contact Activation is performed to attach the activating polymer to one or more cysteine residues of the Exendin variant.
- the specific chemistry of the cysteine of the Exendin variant is separately determined by selecting a specific activating group and a suitable pH value, using different polymeric chain lengths and polymeric structures of polyethylene glycol (PEG). Modification.
- the specific activating group is a maleimide.
- the invention further provides a pharmaceutical composition comprising an Exendin variant and/or an Exendin variant conjugate of the invention, and optionally pharmaceutically acceptable a.
- the invention further provides a method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of an Exendin variant and/or an Exendin variant conjugate and/or pharmaceutical composition of the invention. Accordingly, the invention also provides the use of an Exendin variant and/or Exendin variant conjugate and/or pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of a disease.
- the disease may be selected, for example, from a postprandial dumping syndrome, postprandial hyperglycemia, glucose intolerance, a condition or disease that can be alleviated by inhibiting glucagon secretion, modulating triglyceride levels, reducing food intake, Obesity, eating disorders, insulin resistance syndrome, diabetes, hyperglycemia and hypoglycemia.
- the disease is diabetes, more preferably type I diabetes or type II diabetes, especially type II diabetes.
- Exendin can reduce the body weight of obese patients and can cause nausea and vomiting.
- the mechanism of action is related to the inhibition of the feeding center and the stimulating vomiting in the central nervous system. Larsen. Mechanisms behind GLP-1 induced weight loss. Br J Diabetes Vase Dis 2008; 8: S34-S41; Schick et al. Glucagonkin peptide 1 (7-36)- RACE at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1427-35 ) However, the conjugate of Exendin or its variants is difficult to penetrate the blood-brain barrier due to the increased molecular weight, thereby reducing the vomiting reaction caused by Exendin.
- the present invention provides a method of reducing body weight using a conjugate of Exendin or a variant thereof and/or a pharmaceutical composition comprising such a conjugate, and additionally providing Exendin or a variant thereof Use of a conjugate and/or a pharmaceutical composition comprising such a conjugate in the manufacture of a medicament for reducing body weight.
- the conjugate of Exendin or a variant thereof is an Exendin variant conjugate of the invention described above.
- Fig. 1 is a chart showing the mass spectrum of PB-105 obtained in Example 1.
- Figure 2 illustrates a molecular structure of PEG.
- Figure 3 illustrates the PB-110 obtained by HPLC analysis of Example 2.
- Figure 4 illustrates the molecular structure of PEG5000b.
- Figure 5 illustrates the molecular structure of PEG5000C.
- Figure 6 is a (A) iodine stained image of PB-105 PEGylated conjugate and (B) Coomassie blue stained image, wherein each lane represents the following: 1. Molecular weight standard, 2 ⁇ PB-106 (PEG20000 -PB-105), 3. PB-107 (PEG30000-PB-105), 4. PB-108 (PEG40000-PB-105), and 5. PB-109 (PEG20000*2-PB-105).
- Figure 7 is a graph showing the results of purity analysis of PB-106 (PEG20000-PB-105) obtained by HPLC analysis of Example 3.
- Figure 8 illustrates the molecular structure of PEG20000b.
- Figure 9 illustrates the molecular structure of PEG20000C.
- Figure 10 illustrates the molecular structure of PEG20000d.
- Figure 11 illustrates the molecular structure of PEG20000e.
- Figure 12 is a graph showing the PB-112 obtained by HPLC analysis of Example 3.
- Figure 13 is a graph showing the results of purity analysis of PB-107 (PEG30000-PB-105) obtained by HPLC analysis of Example 4.
- Figure 14 is a graph showing the results of purity analysis of PB-108 (PEG40000-PB-105) obtained by HPLC analysis of Example 5.
- Figure 15 is a graph showing the results of purity analysis of PB-114 (PEG40000-PB-113) obtained by HPLC analysis of Example 5.
- Figure 16 illustrates the molecular structure of PEG20000X2.
- Figure 17 is a graph showing the results of purity analysis of PB-109 (PEG20000*2-PB-105) obtained by HPLC analysis of Example 6.
- Figure 18 illustrates the molecular structure of PEG20000x2b.
- Figure 19 illustrates the molecular structure of PEG20000x2c.
- Figure 20 illustrates the molecular structure of PEG20000x2d.
- Figure 21 is a graph showing the results of purity analysis of PB-119 (PEG23000-PB-105) obtained by analyzing Example 7 by HPLC.
- Figure 22 is a graph showing the results of purity analysis of PB-120 (PEG27000-PB-105) obtained by HPLC analysis of Example 8.
- Figure 23A illustrates PB-106 (PEG20000-PB-105) at ⁇ 4 ⁇ 5 and -20. C saved the results of HPLC analysis after 60 days.
- Figure 23B illustrates PB-106 (PEG20000-PB-105) at ⁇ 7 ⁇ 0 and 4. C saved the results of HPLC analysis after 60 days.
- Figure 23C illustrates PB-106 (PEG20000-PB-105) at ⁇ 7 ⁇ 0 and -20. C saved the results of HPLC analysis after 60 days.
- Figure 24 is a graph showing the dose-effect relationship of PB-101 and PB-105 on cAMP action in PC12 cells.
- Figure 25 is a graph showing the effect of PB-105 and its PEGylated conjugate on intracellular cAMP activity, 1 in vitro.
- Figure 26A illustrates the correlation of the molecular weight of polyethylene glycol in the PEGylated conjugate with in vitro drug activity (LogEC 5 .).
- Figure 26B illustrates the correlation of the molecular weight of polyethylene glycol in the PEGylated conjugate to the maximum activity of the drug ( Emax ).
- Figure 27 is a graph showing the effect of PB-105 and its PEGylated conjugate on intracellular cAMP activity, 1 in vitro.
- Figure 28 is a graph showing the time-effect relationship of hypoglycemic action of PB-101 and PB-105.
- Figure 29 is a graph showing the dose-effect relationship of PB-101 and PB-105 for hypoglycemic action.
- Figure 30 illustrates the dose-effect relationship of hypoglycemic effect of PB-101 and its variant PB-102.
- Figure 31 illustrates the time-effect relationship of PB-105 and its PEGylated conjugates for equivalent hypoglycemic effects.
- Figure 32A illustrates the correlation of the molecular weight of polyethylene glycol in the PEGylated Exendin variant to the biological half-life (T 1/2 ).
- Figure 32 is a graph showing the correlation between the molecular weight of polyethylene glycol in the PEGylated Exendin variant and the maximum hypoglycemic effect (% pre-dose blood glucose concentration).
- Figure 32C is a graph showing the correlation between the molecular weight of polyethylene glycol in the PEGylated Exendin variant and the Area Above Curve (AAC).
- Figure 33 illustrates the time-effect relationship of PB-105 and its PEGylated (PEG30000) conjugate PB-107 for equivalent hypoglycemic effect.
- Figure 34 illustrates the dose-effect relationship of PB-105 and its PEGylated (PEG20000) conjugate PB-106 for hypoglycemia.
- Figure 35 is a graph showing the time-effect relationship of PB-105, PB-111 and its PEGylated conjugates in the same amount of hypoglycemic effect. Experimental data is expressed as mean soil SEM.
- Figure 36 is a graph showing the time-effect relationship of PB-101 and its variants PB-105, PB-111 and PB-113 and the pegylated conjugates PB-106, PB-112 and PB-114 for hypoglycemia. Experimental data is expressed as mean soil SEM.
- Figure 37 illustrates the time-effect relationship of PB-105 and its PEGylated conjugates for equal hypoglycemic effects. Experimental data is expressed as mean soil SEM. * Representatives were significantly different from the PB-105 group (p ⁇ 0.05).
- Figure 38 is a graph showing the effects of PB-101, PB-105, PB-106 and PB-120 on the vomiting latency (A) and the number of vomiting (B) of the pigeons.
- Experimental data is expressed as mean ⁇ SEM.
- a represents a statistically significant difference (P ⁇ 0.05) between the 3 mg/kg dose and the PB-105 group;
- b represents a difference between the PB-101 and PB-105 groups at the 6 mg/kg dose.
- Statistically significant p ⁇ 0.05).
- Figure 39 illustrates the effect of PB-101, PB-105 and PB-106 on systemic immune allergic responses in guinea pigs.
- the experimental data is represented by mean SEM.
- a represents physiological salt
- the difference in water group was statistically significant (p ⁇ 0.05);
- b was statistically significant compared with PB-101 or PB-105 (p ⁇ 0.05).
- Figure 40 is a graph showing the effects of PB-101, PB-105, and PB-106 on (A) 0-18 days and (B) 0-4 days on guinea pig weight gain.
- Experimental data is expressed as mean ⁇ SEM.
- a represents a statistically significant difference between the saline group and the saline group (p ⁇ 0.05);
- b represents a statistically significant difference ( ⁇ 0.05 ) compared with the Exenatide or PB-105 group.
- Figure 41 is a graph showing the effects of PB-105, PB-106, PB-119 and PB-120 on (A) rat body weight and (C) food intake after administration.
- B and D are the area maps under the body weight-time curve and the area under the food intake-time curve for the corresponding groups of rats after administration.
- Experimental data is expressed as mean soil SEM.
- a represents a statistically significant difference (p ⁇ 0.05) compared with the saline group;
- b represents a statistically significant difference ( ⁇ 0.05) compared with the PB-105 group.
- Figure 42 illustrates a single intravenous injection of Exenatide and PB-105 drug-time curves.
- Figure 43 is a graph showing the single intravenous injection of PB-105 and its PEGylated Exendin conjugate drug-time curve.
- Figure 44A is a graph showing the molecular weight of polyethylene glycol in a PEGylated Exendin variant conjugate as a function of plasma half-life.
- Figure 44B is a graph showing the molecular weight of the polyethylene glycol in the PEGylated Exendin variant conjugate and the area under the drug-time curve (AUC).
- amino acid includes natural amino acids, unnatural amino acids, and amino acid analogs, as well as all their D and L stereoisomers.
- Unnatural amino acids include, but are not limited to, azetidine carboxylic acid, 2- Aminoadipate, 3-aminoadipate, ⁇ -alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminohexanoic acid, 2-aminoheptanoic acid, 2-aminoiso Butyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, tert-butylglycine, 2,4-diaminoisobutyric acid, 2,2,-diaminopimelic acid, 2,3-diamino Propionic acid, N-ethylglycine, N-ethyl asparagine, homoproline, hydroxylysine, beta-hydroxylysine, 3-hydroxyproline, 4-
- Amino acid analogs include natural amino acids and unnatural amino acids, such as methionine, which are chemically blocked reversibly or irreversibly at their C-terminal carboxyl group, N-terminal amino group or a side chain group thereof, or chemically modified into another functional group.
- polypeptide or "protein,” as used herein, interchangeably refers to a string of at least two amino acid residues joined to each other by a covalent bond (eg, a peptide bond), which may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide. .
- a covalent bond eg, a peptide bond
- cyste substitution refers to the replacement of one or more other amino acid residues in a natural polypeptide (eg, Exendin-4) with a cysteine residue by, for example, genetic engineering or artificial chemical synthesis. base.
- polypeptide variant refers to a polypeptide that differs in amino acid sequence by one or more substitutions, deletions, insertions, fusions, truncations, or any combination thereof.
- a variant polypeptide can be fully functional or can lack the function of one or more activities.
- a fully functional variant may contain, for example, only a conservation change or a change in a non-critical residue or a non-critical region.
- Functional variants may also include substitutions of similar amino acids that result in unaltered or insignificant changes in function.
- Amino acids that are important for function can be identified by methods known in the art, such as site-directed or glycine scanning (Cunningham, ⁇ and Wells, J., Science, 244: 1081-1085, 1989). Sites critical for polypeptide activity can be determined, for example, by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith, L et al, J. Mol. Biol., 224: 899-904, 1992; de Vos, A. et al., Science, 255: 306-312, 1992).
- the term "mercaptomeric variant” refers to a polypeptide variant having a thiol group in the amino acid sequence by substitution, insertion, fusion or any combination thereof.
- conjugate refers to a product formed by the covalent or non-covalent attachment of a polypeptide or polypeptide variant to a modifying group as described herein, said modifying group comprising However, it is not limited to the examples described above.
- modified polypeptide refers to a polypeptide or polypeptide variant in which one or more amino acids are chemically modified, wherein the modification refers to the covalentity of different types of groups.
- non-covalent modifications including but not limited to: phosphorylation, glycosylation, methylation, PEGylation, biotinylation, SUMO, acylation, and the like.
- alkyl denotes a substituted or unsubstituted straight or branched alkyl group, such as C1-C30 alkyl, C1-C20 alkyl, C2-C15 alkyl or C3-C10 alkyl, wherein Optionally, there may be one or more substituents independently selected from, for example, halogen, amino, nitro, and the like.
- cycloalkyl denotes a substituted or unsubstituted C3-C8 cycloalkyl group, which may optionally have one or more substituents independently selected from, for example, the following: C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, halogen, amino, nitro, and the like.
- alkenyl denotes a substituted or unsubstituted straight or branched alkenyl group having one or more carbon-carbon double bonds therein, which may have, for example, 2 - 20, 3 - 15, 4 - 10 carbon atoms, and optionally having one or more substituents independently selected from, for example, halogen, amino, nitro, and the like.
- aryl denotes a C6-C10 aryl group, which is optionally substituted by one or more substituents independently selected from, for example, C1-C10 alkyl, C2-C10 alkenyl. , C2-C10 alkynyl, halogen, amino, nitro, and the like.
- linking group denotes an organic group which links PEG to Exendin.
- the linking group may be an alkyl group, an ether group, an amide group, an ester group, a thio group or the like, which may contain, for example, up to 30 carbon atoms, such as 1 - 25, 2 - 20, 3 - 15 or 3 - 10 carbon atoms.
- polyethylene glycol has the meaning commonly understood by one of ordinary skill in the art, including both polyethylene glycol itself and derivatives modified at the end thereof, unless specifically stated otherwise.
- the average molecular weight is generally used to indicate the molecular weight of the polymer, specifically, the number average Molecular weight or weight average molecular weight. Although there may be some deviation between the number average molecular weight and the weight average molecular weight when the degree of polymerization of the polymer is large, the two tend to be equal for a polymer having a narrow distribution range.
- polymers mentioned herein, such as polyethylene glycol when referring to its molecular weight, it may be either a weight average molecular weight or a number average molecular weight.
- One aspect of the invention relates to an Exendin variant having GLP-1 receptor agonist activity having one or more of Exendin wild type sequences or similar sequences thereof, such as 1, 2, 3, 4, 5 An amino acid sequence in which more or more amino acid residues are replaced by a cysteine.
- the cysteine substitutions may each independently be independent of the N-terminus, C-terminus or internal of the Exendin variant sequence.
- the Exendin variant has a cysteine substitution at least at 1, 2, 3 or 4 amino acid residues at its C-terminus.
- the last amino acid of the C-terminus of the Exendin variant is replaced by a cysteine.
- the Exendin variant has a cysteine substitution at its C-terminus, N-terminus and/or internal 1, 2, 3, 4 or more amino acid residues.
- Exendin wild type sequence or similar sequence described in the present invention may be any sequence known in the art, including various variants or analogs thereof or agonist sequences thereof.
- Guidance on Exendin can be found, for example, in Eng J. et al, J. Biol. Chem., 265: 20259-62, 1990; Eng J. et al, J. Biol. Chem., 267: 7402-05, 1992; /66629 and WO00/41546, etc., the entire contents of which are incorporated herein by reference.
- the Exendin variants of the invention may also optionally have one or more, for example 1, 2, 3, 4, 5 or more further amino acid modifications including, for example, amino acid substitutions, deletions, insertions and/or additions. .
- the further amino acid modifications may each independently be located at the N-terminus, C-terminus and/or internal of the Exendin sequence.
- the amino acids substituted, inserted and/or added may be any natural amino acid, unnatural amino acid or amino acid analog, or their D or L stereoisomers.
- the further amino acid modification is a conservative amino acid substitution, such as Ala/Gly, Ser/Thr, Glu/Asp, Gln/Asn, Ala/Val/Ile/Leu, Arg/Lys, Phe/Tyr Replace each other.
- conservative amino acid substitutions see, for example, WO/2006/083301, etc. This is incorporated herein by reference.
- the wild type Exendin may be Exendin-3 or
- the invention relates to an Exendin variant having an amino acid sequence
- the Exendin variant has a cysteine substitution at least at one or more positions selected from the group consisting of: SEQ ID NO: 1 or SEQ ID NO: 2 at position 20 Arg (arginine), The position corresponding to 25 Trp (tryptophan), 35 Ala (alanine) and 39 Ser (serine).
- the Exendin variant has an amino acid sequence selected from the group consisting of:
- the amino acid modifications may each independently be located at the N-terminus, C-terminus and/or internal of the Exendin sequence.
- the substituted, inserted and/or added amino acids may be any natural amino acid, unnatural amino acid or amino acid analog, or their D Or L stereoisomers.
- the further amino acid modification is a conservative amino acid substitution, such as Ala/Gly, Ser/Thr, Glu/Asp, Gln/Asn, Ala/Val/Ile/Leu, Mutual substitution between Arg/Lys, Phe/Tyr, and the like.
- Exendin variants of the invention can be obtained by a variety of means well known in the art, including, for example, recombinant methods of preparation, chemical synthesis, and the like.
- the Exendin variants of the invention are chemically synthesized by solid phase peptide synthesis techniques and then purified on a laboratory scale, such as by a single purification step on a reverse phase HPLC column or by other suitable chromatography methods.
- an Exendin variant of the invention is produced by recombinant methods, including, for example, expression in a suitable prokaryotic or eukaryotic host cell, and the Exendin variant of the invention is isolated therefrom by conventional techniques.
- a nucleotide sequence encoding the peptide can be first synthesized by chemical synthesis, and the sequence is subsequently cloned into a suitable expression vector for expression under the control of a suitable promoter.
- a nucleotide sequence encoding an Exendin variant can be obtained from a wild-type Exendin using a mutagenesis method such as PCR mutagenesis, and then the sequence is cloned into a suitable expression vector and expressed under the control of a suitable promoter.
- a mutagenesis method such as PCR mutagenesis
- Suitable eukaryotic host cells are mammalian cells such as CHO, COS, HEK 293, BHK, SK-Hep and HepG2. The cells are preferably grown under conditions suitable for expression of the Exendin variants of the invention.
- the reagents and conditions for producing or isolating the Exendin variant of the present invention there is no particular limitation, and any system known in the art or commercially available can be used.
- the Exendin variant is obtained by methods already described in the art.
- Prokaryotic expression vectors can include, for example, plasmids such as pRSET, pET, and pBAD, among which promoters such as lac, trc, trp, recA or araBAD can be employed.
- Eukaryotic expression vectors include: (i) vectors for expression in yeast such as pAO, pPIC, YES, MET, wherein promoters such as AOX1, GAP, GAL1, AUG1, etc.
- Retroviruses and the like among which promoters such as CMV, SV40, EF-1, UbC, RSV, ADV, BPV and ⁇ actin can be used.
- the Exendin variant is expressed in a prokaryotic or eukaryotic cell system and a codon-optimized coding sequence is used.
- the sequence expressing the Exendin variant comprises a leader peptide and/or a signal peptide to facilitate secretion of the Exendin variant from the cell to the outside of the cell for isolation and purification.
- the sequence expressing the Exendin variant does not comprise a leader peptide and/or a signal peptide which is not secreted extracellularly and is isolated and purified by lysing the cells.
- the Exendin variants of the invention can be conjugated to one or more polymeric groups to form an Exendin variant conjugate.
- polymer is preferably physiologically acceptable, including being soluble in an aqueous solution or suspension, and having no adverse effects on the mammal, such as side effects, after administration of the polymer-Exendin conjugate in a pharmaceutically effective amount.
- Polymer which can be used in the present invention is not particularly limited.
- the polymer generally preferably has from 2 to about 3000 repeating units.
- the polymer group may be selected from natural or synthetic polymers, examples of which include, but are not limited to, for example, polysaccharides, polyalkylene glycols such as polyethylene glycol (PEG), polypropylene glycol (PPG), polyethylene oxide ( PEO), a copolymer of ethylene glycol and propylene glycol, polyvinyl alcohol, or the like, or any combination thereof.
- PEG polyethylene glycol
- PPG polypropylene glycol
- PEO polyethylene oxide
- a copolymer of ethylene glycol and propylene glycol polyvinyl alcohol, or the like, or any combination thereof.
- one or more PEG groups are used in the Exendin variant conjugates of the invention for conjugation modification.
- the polymer is not limited to a specific structure, and it may be linear (such as alkoxy PEG or bifunctional PEG), branched or multi-armed (such as bifurcated PEG or linked to a polyol core). PEG ), dendritic or may have a degradable linkage.
- the internal structure of the polymer may be organized in any number of different modes, which may be selected from the group consisting of homopolymers, alternating copolymers, random copolymers, block copolymers, alternating trimers, random terpolymers, and embedded Segmental trimer and the like.
- the polymer may also include a poly(alkylene oxide) polymer, polymaleic acid, poly(D,L-alanine), and the like.
- the polymer is polyethylene glycol (PEG) or a derivative thereof such as methoxypolyethylene glycol (mPEG).
- PEG polyethylene glycol
- the polyethylene glycol (PEG) includes both a terminal group having a hydroxyl group and a terminal group having another group.
- Such other groups include, but are not limited to, alkoxy, cycloalkoxy, cycloalkyloxy, alkenyl, aryloxy or aralkyloxy.
- PEG molecule types are known in the art and are routinely used in polypeptide modification.
- the PEG side chain can be linear, branched, bifurcated or composed of multiple arms, and different polyethylene glycols can have different polymeric chain lengths and polymeric structures.
- the molecular weight of the PEG used in the present invention is not particularly limited, and its molecular weight may range from 0.1 to 200 kDa, for example, from 1 to 150 kDa, from 2 to 100 kDa, from 3 to 80 kDa or from 4 to 50 kDa, and may also be from 5 to 40. kDa.
- a particularly useful PEG has a molecular weight in the range of 5 to 30 kDa.
- Other useful PEG molecules include those disclosed in, for example, WO 03/040211, US 6,566,506, US 6,864,350, and US 6,455,639.
- the PEG has the formula HO-CH 2 CH 2 0-(CH 2 CH 2 0) n -CH 2 CH 2 -OH, wherein n ranges from about 5 to 4,000.
- PEGs of the invention include PEGs with other terminal groups, such as methoxy PEG, branched PEG, bifurcated PEG, and the like. Suitable branch PEG The preparation can be carried out as described in U.S. Patent No. 5,932,462, the entire disclosure of which is incorporated herein by reference.
- the bifurcated PEG refers to a PEG having a branch near one end of the polymer chain, and the main chain of the bifurcated PEG may be linear or branched.
- the present inventors have unexpectedly discovered that in the Exendin variant conjugates of the invention, even if the molecular weight of the polymeric group (e.g., PEG) is increased to 30 kDa, compared to the unconjugated Exendin variant
- the conjugate molecule still retains most of the GLP-1 receptor agonist activity (eg, in vivo activity).
- the Exendin variant conjugate of the present invention retains comparable GLP-1 receptor agonist activity (e.g., in vivo activity) even when the molecular weight of PEG is increased to 40 kDa or higher.
- the GLP-1 receptor agonist of the Exendin variant conjugate is compared to the unconjugated Exendin variant.
- the activity is basically unchanged.
- the invention provides an Exendin variant conjugate having an extended biological half-life and significant GLP-1 receptor agonist activity.
- the one or more polymer groups (such as PEG) have a molecular weight of from 2 kDa to 50 kDa, preferably from 3 kDa to 40 kDa, more It is preferably 4 kDa to 35 kDa, and further preferably 5 kDa J. 30 kDa, such as 5 kDa, 10 kDa, 15 kDa, 20 kDa, 30 kDa and 40 kDa and any value between the above respective molecular weight values.
- the one or more polymer groups (such as PEG) have a molecular weight of from 20 kDa to 30 kDa, preferably from 21 kDa to 29 kDa, more Preferably 23 kDa to 27 kDa, such as 20 kDa, 21 kDa, 22 kDa, 23 kDa, 24 kDa, 25 kDa, 26 kDa, 27 kDa, 28 kDa, 29 kDa, 30 kDa and any value between the above molecular weight values .
- the polymers used in the present invention are known in the art and can be obtained by a variety of routes including, for example, commercially available, such as CarboMer, Inc., JT Baker, The Dow Chemical Company, etc., or Methods known in the art are prepared by themselves, for example as described in EP 1245608.
- the invention is not limited to polymers made by any particular method.
- the at least one polymer may be coupled to Exendin via an amino group, a carboxyl group, a hydroxyl group, and/or a thiol group on Exendin.
- groups are typically located on the alpha-amino, alpha-carboxy and side chains of amino acid residues such as lysine, aspartic acid, glutamic acid, cysteine and the like.
- one or more polymer molecules are coupled to the Exendin variant via a thiol group of a cysteine in the Exendin variant.
- Polymerization of a thiol group of a cysteine residue in a protein, such as polyethylene glycol, can improve the selectivity of the modification because there are many reagents that specifically react with the thiol group, and useful thiol groups in the protein are, for example, lysine. The free amino groups of the acid residues are much less.
- the one or more polymeric groups can be conjugated to a cysteine residue of an Exendin variant, more preferably conjugated to a half of an Exendin variant with a thioether linkage.
- the Exendin variant has one or more cysteine substitutions at positions corresponding to positions 20, 25, 35 and/or 39 of wild type exendin-3 or exendin-4, and It is coupled to a polymer such as polyethylene glycol via its thiol group.
- the Exendin variant has a cysteine substitution at a position corresponding to position 35 and/or position 39 of wild type exendin-3 or exendin-4.
- the Exendin variant has a cysteine substitution at a position corresponding to position 39 of wild type exendin-3 or exendin-4.
- the polymeric group is conjugated to a cysteine residue of the Exendin variant of the invention as a thioether linkage.
- a thioether bond can be formed between the alkenyl group of the maleimide and the sulfhydryl group of the cysteine, thereby one or more A polyethylene glycol group is conjugated to the cysteine residue of the Exendin variant of the invention.
- PEGylation of a cysteine residue can also be carried out by using, for example, PEG-vinylsulfone, PEG-iodoacetamide or PEG-thiopyridylpyridine.
- a variety of methods for conjugating polymeric groups such as PEG to polypeptides are known in the art and can be used in the present invention.
- PEGylated Exendin As used herein, “PEGylated Exendin”, “PEG modified Exendin,” or “Exendin variant-PEG conjugate” includes Exendin variants conjugated to one or more PEGs. As used herein, “PEG , “, or “PEG modification” includes conjugating one or more PEG groups to Exendin. Suitable PEGylation methods are disclosed in, for example, U.S. Patent No. 5,122,614 and U.S. Patent No. 5,539,063, the entire disclosure of which is incorporated herein by reference. In some embodiments, the conjugate has the structure of formula (I):
- Exendin represents an Exendin variant of the invention
- Y is H or RPEG _ X-
- each X and Z are each independently a linker
- PEG represents
- R represents a terminal group of PEG, preferably each R is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl , aryl or aralkyl.
- the alkyl group can be a C1-C6 alkyl group, preferably a C1-C4 alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and a tert-butyl group;
- the cycloalkyl group may be a C3-C7 cycloalkyl group such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group and a cycloheptyl group;
- the cycloalkylalkyl group may be a cycloalkyl group a C1-C4 alkyl group, such as a cycloalkylmethyl group and a cycloalkylethyl group, including a cyclohexylmethyl group and a cyclohexylethyl group; and the like
- each " RPEG " described in formula (I) independently has the structure:
- Each " RPEG " described in ) has the following structure independently:
- each of the formulas described in formula (I) has the following structure independently:
- each "one X" of the formula (I) independently has the following structure:
- Exendin variant conjugates of the invention can be prepared by any suitable method.
- a variety of methods are known in the art for conjugating a polymer to a protein or peptide, including incubating the Exendin variant of the invention with a polymer, preferably an activated polymer, under suitable conditions.
- the polymer is polyethylene glycol, which can be activated and conjugated to, for example, cyanogen bromide, abalone diimidazole, N-hydroxysuccinimide, cyanuric chloride, and the like.
- Exendin variant is polyethylene glycol, which can be activated and conjugated to, for example, cyanogen bromide, abalone diimidazole, N-hydroxysuccinimide, cyanuric chloride, and the like.
- PEG can be specifically conjugated to a cysteine residue in an Exendin variant by PEG-maleimide, PEG-vinyl anthracene, PEG-substituted acetamide or PEG-platinyl-n-pyridine. On the base of the base.
- the activated PEG is incubated with the Exendin variant of the invention under the following conditions: pH 5.0-7.0, PEG to peptide molar ratio 1-10, reaction time 0.5-12 hours , the reaction temperature is 0-50 ° C, for example 2-40. C or 4-37. C.
- the conjugate can be isolated by a suitable method. Suitable methods include, for example, ultrafiltration, dialysis or chromatography, etc., all of which are within the abilities of one of ordinary skill in the art.
- the Exendin variants and/or Exendin variant conjugates of the invention can be used in a variety of applications including, for example, for lowering blood glucose.
- the present invention also provides a pharmaceutical composition for lowering blood glucose comprising a therapeutically effective amount of an Exendin variant and/or an Exendin variant conjugate of the present invention, and optionally a pharmaceutically acceptable carrier .
- the pharmaceutical composition is useful for the treatment of diabetes, more preferably for the treatment of type 1 diabetes and/or type II diabetes, particularly preferably for the treatment of type 2 diabetes.
- an Exendin variant or Exendin variant conjugate of the invention will depend on the route of administration, the type of subject, and the physical characteristics of the particular mammal in question. These factors and their relationship to the determination of this amount are well known to those skilled in the medical arts. This amount and method of administration can be adjusted to achieve optimal efficacy to deliver the peptide to the subject, but will depend on factors well known to those skilled in the medical arts such as body weight, diet, concomitant medication, and other factors.
- compositions of the invention may be administered in combination therapy, i.e., in combination with one or more other agents, wherein the therapeutic agents are administered together, or sequentially.
- the additional agent can be administered before, during or after administration of one or more Exendin variants and/or Exendin variant conjugates of the invention or a pharmaceutical composition thereof.
- Such other agents which can be used in the present invention include, for example, agents which lower blood sugar, such as insulin, insulin analogs, dextrin agonists and cholestyramine, and/or other compounds or compositions for treating diseases.
- such combination can achieve combined, even synergistic effects.
- pharmaceutically acceptable carrier As used herein, “pharmaceutically acceptable carrier”, “pharmaceutically acceptable carrier” or “physiologically acceptable carrier” are used interchangeably and include any and all physiologically compatible salts, solvents, dispersion media, coatings. , one or more of an antibacterial and antifungal agent, an isotonic and absorption delaying agent, and the like.
- the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or bolus injection).
- the therapeutic agent may be coated with a material to protect the therapeutic agent from the action of acids and other natural conditions which may deactivate the therapeutic agent.
- the pharmaceutical preparation of the present invention When administered, the pharmaceutical preparation of the present invention is administered in a pharmaceutically acceptable amount in a pharmaceutically acceptable amount.
- pharmaceutically acceptable means a non-toxic substance that does not interfere with the biologically active efficacy of the active ingredient.
- Such preparations usually contain salts, buffers, preservatives, compatible carriers, and Other therapeutic agents are selected, such as supplemental immunopotentiators, including adjuvants, chemokines, and cytokines.
- the salt should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts can be conveniently used in the preparation of pharmaceutically acceptable salts thereof, and they are not excluded from the scope of the present invention.
- Exendin variants or Exendin variant conjugates of the invention can be combined with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier refers to one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration to a mammal, such as a human.
- carrier means an organic or inorganic, natural or synthetic ingredient which is combined with the active ingredient for ease of application.
- the components of the pharmaceutical composition can also be co-mixed in the absence of an interaction which significantly destroys the desired therapeutic effect of the drug. .
- the pharmaceutical composition of the present invention may comprise a buffer system, preferably the buffer system is an acetate buffer solution having a pH of from about 3.0 to about 6.0, or a phosphate buffer having a pH of from about 5.0 to about 9.0. Flush the solution.
- suitable buffering agents include acetate; citrate; borate; phosphate.
- compositions may also contain suitable preservatives, for example: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
- suitable preservatives for example: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
- the pharmaceutical composition may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. All methods include the step of combining the active agent with a carrier comprising one or more accessory ingredients. In general, the composition is prepared by uniformly and intimately combining the active compound with a liquid carrier, a finely divided solid carrier or both, optionally shaping the product.
- a pharmaceutical composition suitable for parenteral administration can be a sterile aqueous or nonaqueous preparation comprising one or more Exendin variants or Exendin variant conjugates.
- the formulation is isotonic with blood of the subject.
- This formulation can be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspension medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Carrier suitable for oral, subcutaneous, intravenous, intramuscular, etc. Formulations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co" Easton, PA.
- Exendin variants or Exendin variant conjugates of the invention can be prepared with carriers that protect them from rapid release, such as controlled release formulations, including implants, transdermal patches, and microcapsule delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
- a number of methods for preparing such formulations are known in the art, see, for example, Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978, and the like.
- compositions of this invention may be administered by any conventional route, including injection or gradual infusion over time.
- the administration can be oral, intravenous, intraperitoneal, intramuscular, intraluminal, intratumoral, or transdermal.
- compositions of the invention are administered in an effective amount.
- “An effective amount is any amount of an Exendin variant or Exendin variant conjugate provided herein that produces a desired response, either alone or in combination with a further dose and/or other therapeutic agent (eg, lowering blood glucose in a subject) Level) This may include only temporarily slowing the progression of diabetes, or in some embodiments, including permanently stopping the development of diabetes.
- compositions used in the foregoing methods are preferably sterile and contain an effective amount of an Exendin variant or Exendin variant, alone or in combination with another formulation, in a weight unit or volume unit suitable for administration to a patient.
- the conjugate to produce a desired response, such as a decrease in blood glucose.
- the dosage of the Exendin variant or Exendin variant conjugate administered to the subject can be selected according to different parameters, particularly depending on the mode of administration used and the state of the subject. Other factors include the desired treatment period. If the response in the subject is insufficient at the initial dose applied, a higher dose (or an effective higher dose achieved by a different, more localized delivery route) can be applied to a range that is tolerated by the patient.
- the pharmaceutical compositions of the invention comprise 0.20 mg/ml to 5 mg/ml Exendin variant and/or comprise 4 mg/ml to 40 mg/ml Exendin variant conjugate, preferably 0.20 mg/ml ⁇ 5 mg/ml Exendin variant and/or containing 4 mg/ml ⁇ 40 mg/ml Exendin variant conjugate, more preferably 0.5 mg/ml ⁇ 2 mg/ml Exendin variant and/or containing 10 mg/ml ⁇ 20 mg/ml Exendin variant conjugate.
- dosages of Exendin variants or Exendin variant conjugates of the invention can range from about 10 g/kg patient body weight to about 100,000 g/kg patient body weight.
- the dosage can range from about 0.1 mg/kg to about 20 mg/kg. In other embodiments, the dosage may range from about 0.1 mg/kg to 5 mg/kg, 0.1 mg/kg to 10 mg/kg, or 0.1 mg/kg to 15 mg/kg. In other embodiments, the dosage may range from about 1 mg/kg to 5 mg/kg, 5 mg/kg to 10 mg/kg, 10 mg/kg to 15 mg/kg or 15 mg/kg to 20 Mg/kg.
- the dosage is about 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 7 mg/kg, 10 mg/ Kg, 12 mg/kg, 15 mg/kg, 17 mg/kg, 20 mg/kg, 25 mg/kg or 30 mg/kg. In another embodiment, the dosage is about 1 mg/kg, 3 mg/kg, 5 mg/kg or 6 mg/kg. Based on the composition, the dose can be delivered continuously (e.g., by a continuous pump) or at periodic intervals. In some embodiments, the dosage of the Exendin variant or Exendin variant conjugate of the invention may range from 0.1 to 20 mg/kg or any value therein when administered intravenously.
- the desired time interval for multiple administrations of a particular composition can be determined by one skilled in the art without undue experimentation.
- Other dosage regimens for the compositions provided are known to those skilled in the art, wherein the dosage, schedule of administration, site of administration, mode of administration, and the like can vary from the foregoing.
- the dose is administered intravenously.
- the agent administration regimen is a single intravenous administration.
- Kits comprising Exendin variants or Exendin variant conjugates (e.g., in pharmaceutical compositions) and instructions for use are also within the scope of the invention.
- the kit may additionally contain at least one other agent, such as one or more other blood glucose lowering agents.
- the kit may comprise a carrier that is compartmentalized to contain one or more container devices or a series of container devices (eg, test tubes, tubes, flasks, bottles, syringes) in a tightly fixed manner therein. Wait).
- the components of the kit may be packaged in an aqueous medium shield or in a lyophilized form.
- compositions provided herein can be in lyophilized form or provided in an aqueous medium.
- the subject is a vertebrate, more preferably a mammal, most preferably a human, but may also be other animals, such as domestic animals (such as dogs, cats, etc.), livestock (such as cattle, sheep, pigs). , horses, etc.) or experimental animals (such as monkeys, rats, mice, rabbits, guinea pigs, etc.).
- Exendin variants and/or Exendin variant conjugates of the invention may be administered alone, but are preferably administered as a pharmaceutical composition, which typically comprises a suitable pharmaceutical excipient, diluent or selected according to the intended mode of administration. Carrier. It can be applied to the patient/subject in need of treatment by any suitable means. The exact dose will depend on a number of factors, including the accuracy of the Exendin variant and the Exendin variant conjugate.
- Some suitable modes of administration include, but are not limited to, oral, rectal, nasal, topical (including buccal and sublingual), subcutaneous, vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and hard) Administration outside the brain.
- the pharmaceutical compositions of the present invention comprise an isotonicity adjusting agent and/or a preservative, preferably the isotonicity adjusting agent is one or more of sucrose, mannitol, sodium chloride, and glycerol.
- the preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and butyl p-hydroxybenzoate.
- Exendin variant or Exendin variant conjugate of the present invention can well prepare by using, for example, isotonic excipients such as physiological saline, Ringer's injection or lactated Ringer's injection. A suitable solution. Stabilizers, buffers, antioxidants and/or other additives may also be added as required.
- the pharmaceutical composition for oral administration may be in the form of a tablet, a capsule, a powder or an oral solution. Tablets may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions typically include a liquid carrier such as water, petroleum, animal or vegetable oil, mineral oil or synthetic oil.
- the pharmaceutical composition is In the form of a liquid formulation and/or a lyophilized formulation, preferably the lyophilized formulation contains a lyoprotectant, more preferably the lyoprotectant is selected from the group consisting of sugars such as sucrose, lactose, mannitol, trehalose and the like.
- Exendin variants and/or Exendin variant conjugates described herein are preferably administered to a subject in a "therapeutically effective amount,” or “effective amount.”
- the composition is preferably administered to the subject in a "therapeutically effective amount” which is sufficient to demonstrate its benefit to the subject.
- the actual amount administered, as well as the rate and time course of administration, will depend on the condition and severity of the subject being treated.
- the prescription for treatment e.g., determining the dosage, etc.
- the dosage of the Exendin variant and/or the Exendin variant conjugate can range from 30 mg/kg body weight/day to 0.00001 mg/kg body weight/day, or 3 mg/kg/day to 0.0001 mg/kg/day, or 0.3 mg/kg/day to 0.01 mg/kg/day.
- the invention also provides a method of treating a disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of an Exendin variant and/or an Exendin variant conjugate.
- the disease is selected from the group consisting of: postprandial dumping syndrome, postprandial hyperglycemia, impaired glucose tolerance, obesity, eating disorders, insulin resistance syndrome, diabetes, and hyperglycemia.
- the disease is type II diabetes.
- Exendin can reduce the body weight of obese patients and can cause nausea and vomiting.
- the mechanism of action is related to the inhibition of the feeding center and the stimulating vomiting in the central nervous system. Larsen. Mechanisms behind GLP-1 induced weight loss. Br J Diabetes Vase Dis 2008; 8: S34-S41; Schick et al.
- Glucagonkin peptide 1 (7-36)-RACE acts at lateral and medial hypothalamic sites to suppress feeding in rats.
- Am J Physiol Regul Integr Comp Physiol 2003; 284: Rl 427-35 and the conjugate of Exendin or its variants, due to the increased molecular weight, is difficult to penetrate the blood-brain barrier, thereby reducing the vomiting reaction caused by Exendin.
- the present invention provides a method of reducing body weight using a conjugate of Exendin or a variant thereof and/or a pharmaceutical composition comprising such a conjugate, and additionally providing Exendin or a variant thereof Use of a conjugate and/or a pharmaceutical composition comprising such a conjugate in the manufacture of a medicament for reducing body weight.
- the conjugate of Exendin or a variant thereof is an Exendin variant conjugate of the invention described above.
- Peptide synthesis has become a common technology in the fields of biochemistry and pharmacy.
- There are many commercial organizations such as GE HealthCare, Applied Biosystems Inc., etc. that can commercially supply many types of peptide synthesizers, and there are already many commercial organizations (such as Shanghai).
- Shenggong Bioengineering Technology Service Co., Ltd., Shanghai Bocai Biotechnology Co., Ltd., etc. provide customized synthesis services for peptides.
- a polypeptide synthesizer can be used to synthesize a polypeptide having a specified sequence using the following method.
- Exendin-4 and its thiol variant were synthesized using the Fmoc amino protection strategy using a solid phase support of the "Fmoc-Rinker Amide MBHA Resin" type.
- Step 1 The Fmoc-protected amino acid is reacted with HBTU/DIPEA as a condensing agent in N,N-dimethylformamide (DMF) solvent for 1-5 hours, and the condensation reaction is monitored by the ninhydrin method. complete.
- the second step 10-30% piperidine is used as a deprotecting reagent, and reacted in DMF solvent for 10-30 minutes, and the amino protecting group is completely removed by the ninhydrin method.
- Step 3 Repeat the "first step and second step” according to the target polypeptide sequence, using the corresponding amino acids in turn, until the last amino acid in the sequence is coupled.
- Step 4 Trifluoroacetic acid (TFA) as a lysis reagent, react for 1-5 hours, The polypeptide is cleaved from the solid support while removing various protecting groups.
- Step 5 Precipitate the decomposed peptide solution with diethyl ether; collect the precipitate by filtration, then elute with a mobile phase using a C18 type column, select 0.1% TFA/acetonitrile-water system, collect the component solution, freeze-dry The product was obtained.
- Step 6 The purity of the product was identified by high performance liquid chromatography, and the product structure was determined by amino acid sequence analysis and mass spectrometry.
- PB-101 wild type Exendin-4, its amino acid sequence is:
- PB-102 Exendin-4 variant of cysteine (Cys) at position C at position C, the amino acid sequence of which is:
- PB-105 Exendin-4 variant of cysteine (Cys) at position 39 of the C-terminus, the amino acid sequence of which is:
- PB-103 Exendin-4 variant of cysteine (Cys) at position 30 of the C-terminus, whose amino acid sequence is:
- PB-104 Exendin-4 variant of cysteine (Cys) at position 25 of the C-terminus, the amino acid sequence of which is:
- PB-111 Exendin-4 variant at position 39, which is replaced by cysteine (Cys) and linked to tyrosine (Tyr), the amino acid sequence of which is:
- PB-113 Exendin-4 variant in which the 2nd glycine (Gly) at the N-terminus is replaced by D-alanine (dAla) and the C-terminal 39th is replaced by cysteine (Cys), the amino acid sequence of which is :
- Figure 1 provides the results of mass spectrometry analysis of PB-105.
- the M+1 peak (molecular weight +1) of PB-105 was determined by MALDI-TOF mass spectrometry to be 4203.3 Da, which is consistent with its theoretical molecular weight (4202.8).
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (H 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (H 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. Content detection About 1 mg of the polypeptide.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (pH 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. The content is detected by about 1 mg of the polypeptide.
- Example 3c Preparation and Analysis of PB-106c (PEG20000c-PB-105)
- Example 3a The rest were the same as in Example 3a, and finally by GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series, with a condition of 0.1 M sodium nitrate solution 10 ml/min), The purity was 97.2%.
- Example 3a The rest were the same as in Example 3a, and finally GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series, conditional 0.1 M sodium nitrate solution 1.0 ml/min elution), The purity was 97.5 %.
- Example 3a The rest were the same as in Example 3a, and finally GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series, conditional 0.1 M sodium nitrate solution 1.0 ml/min elution), The purity was 95.8 %.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (H 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. The content is detected by about 1 mg of the polypeptide.
- the above collected solution was eluted with a gradient of 61/39 to 54/46 (10 min) using a 300 A pore size C4 reverse phase analytical column (Jupiter C4 300A 4.6*250 mm), 0.1% TFA in water/0.1% TFA in acetonitrile (10 min).
- the HPLC analysis sample retention time was 10.6 min with a purity of 98.5% (see Figure 12).
- GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series) was carried out under the conditions of 0 ⁇ 1 M sodium nitrate solution 1.0 ml/min, and the purity was 98.7%.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto 5 column volumes of SP ion exchange with 50 mM sodium acetate buffer (pH 4.5).
- Chromatography column GE, XK16/20 column, macroCap SP packing
- equilibrate 2 column volumes with 50 mM sodium acetate buffer (H 4.5) then linearly increase to 100% in 20 column volumes
- B buffer 50 mM sodium acetate buffer (pH 4.5) containing 1 M NaCl
- the above collected solution was detected by SDS-PAGE gel electrophoresis, and contrast staining was performed using Coomassie blue staining and iodine staining (see Figs. 6A and 6B).
- the sample was analyzed by analytical HPLC using a 300A pore size C4 reverse phase analytical column (Jupiter C4 300A 4.6*250mm), 0.1% TFA in water/0.1% TFA in acetonitrile from 61/39 to 54/46 gradient (10 min).
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (H 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. The content is detected by about 1 mg of the polypeptide.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (H 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. Content detection About 1 mg of peptide.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (pH 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. The content is detected by about 1 mg of the polypeptide.
- the above collected solution was detected by SDS-PAGE gel electrophoresis, and contrast staining was performed using Coomassie blue staining and iodine staining (see Figs. 6A and 6B).
- the sample was analyzed by analytical HPLC using a 300A pore size C4 reverse phase analytical column (Jupiter C4 300A 4.6*250mm), 0.1% TFA in water/0.1% TFA in acetonitrile from 61/39 to 54/46 gradient (10 min). The retention time is 11.5 min and the purity is 100% (see Figure 17).
- Example 6a The rest were the same as in Example 6a, and finally GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series, conditional 0.1 M sodium nitrate solution 10 ml/min elution), The purity is 99.2%.
- Example 6a The rest were the same as in Example 6a, and finally GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series, conditional 0.1 M sodium nitrate solution 10 ml/min elution), The purity was 98.8%.
- Example 6a The rest were the same as in Example 6a, and finally GPC analysis (Shimadzu LC-20AD, SB-802 HQ/SB-803 HQ/SB-804 HQ three-column series, conditional 0.1 M sodium nitrate solution 10 ml/min elution), The purity is 99.2%.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (pH 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes The 50 mM sodium acetate buffer (pH 4.5) was collected at the AKTA Purifier. Content detection About 1 mg of peptide.
- the sample was diluted 5 times with 50 mM sodium acetate buffer (pH 4.5) and loaded onto a 5 column volume SP ion exchange chromatography column (GE, XK16/) with 50 mM sodium acetate buffer (pH 4.5). 20 column, macroCap SP packing), after loading, equilibrate 2 column volumes with 50 mM sodium acetate buffer (pH 4.5), then linearly increase to 100% B buffer (with 1 M NaCl) in 20 column volumes 50 mM vinegar Sodium acetate buffer (pH 4.5)), the elution peak was collected at AKTA Purifier. The content is detected by about 1 mg of the polypeptide.
- PB-110 PEG5000-PB-105
- PB-106 PEG20000-PB-105
- PB-107 PEG30000-PB-105
- PB-108 PEG40000-PB-105
- PB-109 PEG20000 *2-PB-105
- Example 10 Effect of PB-101 and PB-105 on intracellular cAMP activity in vitro PC12 cells were digested and seeded in 24-well plates at a density of 10 5 cells/ml for 48 hours (to 60-70% confluence), discarded. Remove the original culture solution and use phosphate buffer
- PB-101 increased the cAMP content in PC12 cells in a dose-dependent manner, increasing the cAMP maximum (E max ) to 133 ⁇ 2 ⁇ 7 ⁇ 2 pmol/100 (protein), and the EC 50 value. 1.9x10 9 M.
- the effect of PB-105 on cAMP in PC12 cells in vitro is very similar to that of PB-101.
- PB-105 increased cAMP maximum (E max ) to 129 ⁇ 4 ⁇ 6 ⁇ 8 pmol/100 (protein) (PB-105 vs PB-101, P >0.05); EC 50 value was 2.5 ⁇ 10 9 M.
- PC12 cells were digested and seeded in 24-well plates at a density of 10 5 cells/ml for 48 hours (to 60-70% confluence), the original culture solution was discarded, and washed twice with PBS, and 1 ml of 1% BSA was added.
- the instructions of the cAMP enzyme-linked immunoassay kit set up standard groups of different concentrations to establish a standard curve. After the reaction is completed, the light absorption value is measured at 450 nm by the microplate reader, and the corresponding value is read on the standard curve by using the absorption value. The cAMP concentration is finally calculated for the cAMP concentration in the sample. Increased dose-response relationship of intracellular cAMP in vitro by PB-106, PB-107, PB-108, PB-109 and PB-110 using Graphpad Prizm software Calculation.
- the value is 1.3xl0 9 M.
- the PEGylation modification showed a molecular weight (5-40 kDa)-dependent parallel right shift dose-effect curve, which reduced the biological activity of PB-105 (Fig. 25).
- PC12 cells were digested and seeded in 24-well plates at a density of 10 5 cells/ml for 48 hours (to 60-70% confluence), the original culture solution was discarded, and washed twice with PBS, and 1 ml of 1% BSA was added.
- cAMP enzyme immunoassay kit set up standard group of different concentrations to A standard curve was established. After the reaction was completed, the absorbance was measured at 450 nm on the plate reader, and the corresponding cAMP concentration was read on the standard curve using the absorbance value, and finally the cAMP concentration in the sample was calculated. Using the Graphpad Prizm software, PB-105 was used. , PB-119, and PB-120 increase the dose-effect relationship of intracellular cAMP in vitro.
- mice Male Kunming mice (body weight 27-32 g), mice were not fasted and banned before the experiment, and were randomly divided into 3 groups, 6 in each group.
- 0, 1, 2, 4, 8, 12 hours of blood was collected from the tail tip, and blood glucose was measured using the Johnson & Johnson Stable Blood Glucose Meter and supporting test paper. The blood glucose value at different points is the ordinate and the time is the abscissa.
- the aging curve of hypoglycemic effect is established, and the biological half-life of PB-101 and PB-105 hypoglycemic effect is calculated.
- the results are shown in Figure 28.
- the biological half-life of the Exendin-4 variant and the Exendin-4 after cysteine substitution were '7 ⁇ 7 ⁇ 0 ⁇ 2 hrs and 4 ⁇ 4 ⁇ 0 ⁇ 2 hrs ( PB-105 vs PB-101, P>0.05 indicates that the Exendin-4 variant after cysteine substitution at position C at position 39 has a comparable biological half-life to Exendin-4.
- mice Male Kunming mice (body weight 23-27 g), mice were fasted for 3 h before the experiment, but could not be forbidden, and were randomly divided into 16 groups, 18 in each group.
- Blood was collected from the tip of the tail 1 hour after the injection, and blood glucose was measured using the Johnson & Johnson Stable Blood Glucose Meter and supporting test paper. The blood glucose value was plotted on the ordinate and the dose was plotted on the abscissa.
- the dose-response curve for hypoglycemic effect was established (Fig. 29), and the dose-response parameters of PB-101 and PB-105 hypoglycemic effects were calculated using Graphpad Prizm software (E max and ED 50 ).
- E max and ED 50 The results showed that the maximum hypoglycemic efficiencies of single injections of PB-101 and PB-105 were 32.2% and 36.1%, respectively, ED 5 . Values are 0.6 and 1.2 g/kg, respectively.
- the Log ED 50 values of PB-101 and PB-105 were -0.25 ⁇ 0.17 and 0.08 ⁇ 0.20, respectively. (PB-105 vs PB-101, ⁇ >0 ⁇ 05).
- mice Male Kunming mice (body weight 22-26 g), mice were fasted for 3 h before the experiment, but could not be forbidden, and were randomly divided into 18 groups, 6 in each group. Separate subcutaneous injection of equal volume of normal saline (10 ml/kg), ⁇ -101 (0.01, 0.1, 1, 10, 100 g/kg) and C-terminal 35th cysteine Exendin variant PB-102 (0.01, 0.1, 1, 10, 100 g/kg). Blood was collected from the tip of the tail 1 hour after the injection, and blood glucose was measured using the Johnson & Johnson Stable Blood Glucose Meter and supporting test paper.
- PB-105 and its PEGylated conjugate equivalent hypoglycemic aging test Male Kunming mice (body weight 22-26 g), mice were not fasted and banned before the experiment, randomly divided into 6 groups, each Group 12 only.
- the various Exendin variant conjugates used in the assay have a cumulative or significantly higher (PB-106) cumulative hypoglycemic effect compared to the unconjugated PB-105 (see The area on the blood glucose curve), and these Exendin variant conjugates have significantly longer biological half-lives. Further correlation analysis using PEG molecular weight ra.
- PB-105 PEGylated conjugates PB-106, PB-107, PB-108 and PB- 109 significantly prolonged the time of PB-105 hypoglycemic effect (biological half-life t 1/2 ), but in the range of 5-20 kDa PEG molecular weight, the biological half-life is proportional to the molecular weight, and the hypoglycemic effect after 20 kDa The time (biological half-life) remained essentially unchanged (Fig.
- the site-specific PEGylation modification (PB-110 and PB-106) does not significantly affect the maximum hypoglycemic effect of the Exendin variant conjugate (PB-105 activity, respectively) 96%), and when the PEG molecular weight is 30 kDa or higher (PB-107, PB-108 and PB-109), PEGylation significantly reduces its maximum hypoglycemic effect, although these conjugates still have comparable The cumulative hypoglycemic effect and significantly longer biological half-life.
- mice Male Kunming mice (body weight 20-24 g ), mice were fasted for 3 h before the experiment, but could not be forbidden, and were randomly divided into 13 groups, 6 in each group. Separate subcutaneous injections of equal volume of saline (10 ml/kg), ⁇ -105 (0.1, 0.3, 1, 3, 10, 30 g/kg) and equal doses of PEGylation (PEG20000) Conjugate PB-106 (0.1, 0.3, 1, 3, 10, 30 g/kg).
- PB-105 blood was collected from the tip of the tail 1 hour after the injection (peak time of hypoglycemic, see Figures 28 and 31), and the tail of the PB-106 group was collected 4 hours after the injection (peak time of hypoglycemic, see Figure 31).
- Johnson &Johnson's stable blood glucose meter and supporting test strips detect blood sugar.
- the blood glucose value is plotted on the ordinate and the dose is plotted on the abscissa.
- the dose-response curve for hypoglycemic effect is established (Fig. 34), and the dose-response relationship parameters of PB-105 and PB-106 hypoglycemic effects are calculated using Graphpad Prizm software (E min , E max and ED 5 .).
- mice Male Kunming mice (body weight 24-30 g), mice were not fasted and banned before the experiment, and were randomly divided into 4 groups, 6 in each group.
- PB-111 is a PB-105 derivative in which cysteine is linked to tyrosine at the C-terminal 39.
- the biological half-lives of PB-105 and PB-111 were 4.6 hrs and 6.0 hrs, respectively, and the maximum hypoglycemic effects were 44.7% and 36.4%, respectively.
- the biological half-lives of PB-106 and PB-112 are 19.6 hrs and At 21.7 hrs, the maximum hypoglycemic effect was 37.3% and 34.9%, respectively.
- the results indicate that the addition of tyrosine at position C at position C does not affect the hypoglycemic activity and biological half-life of PB-105 and its PEGylated conjugate PB-106.
- Example 20 PB-101 and its variants PB-105, PB-111 and PB-113 and PEGylated conjugates PB-106, PB-112 and PB-114 for hypoglycemia in STZ diabetic mice
- mice were fasted for 14 hours before the model was established, and the blood glucose level was measured by tail tip blood sampling. Then, a new STZ (streptozotocin) was prepared by subcutaneous injection (120 mg/10 ml/kg, freshly prepared, dissolved in pH 4.5). The 0.1M citrate buffer), blood glucose was detected after 3 days, and the random blood glucose of the mice was higher than 16.7 mmol/L. Before the experiment, the mice were not fasted and banned, and they were divided into 7 groups, 4-6 in each group.
- STZ streptozotocin
- PB-101 10 g/10ml/kg
- PB-105 10 g/kg
- PB-106 10 g/kg
- PB. -111 10 g/kg
- PB-112 10 g/kg
- PB-113 10 g/kg
- PB-114 10 g/kg
- PB-111 39 and a half at the C end PB-105 derivative
- PB-113 is a PB-105 derivative in which the 2nd position of the N-terminal glycine is replaced by D-alanine
- PB-114 is a PB-113 PEGylated (PEG40000) conjugate.
- Blood was collected at 0.5, 1, 2, 4, 8, 12, 24, 48 hrs after injection and blood glucose was measured.
- the blood glucose values at different time points were plotted on the ordinate and the time was plotted on the abscissa.
- the aging curves of PB-101, PB-105, PB-106, PB-111, PB-112, PB-113 and PB-114 were established.
- GraphPad Prism 5 Demo software Prism v5, Graphpad Software, Inc., San Diego, CA
- using mathematical statistics to analyze PB-101, PB-105, PB-106, PB-111, PB-112
- the biological half-life t 1/2 of PB-113 and PB-114 is compared.
- Figure 36 shows that a single injection of PB-101, PB-105, PB-106, PB-111, PB-112, PB-113 and PB-114 reduced time-dependent randomized blood glucose in STZ-induced diabetic mice. Its maximum hypoglycemic efficiency was 47.5%, 57.6%, 69.8%, 54.4%, 59.7%, 49.2% and 17.9% (only 38% of PB-101).
- PB-101, PB-105, PB-106, PB-111, PB-112 and The biological half-lives of PB-113 were 5.5, 5.5, 21.8, 5.0, 20.3 and 5.9 hrs, respectively. The biological half-life of PB-114 could not be measured due to the low hypoglycemic effect.
- Example 21 PB-105 and its PEGylated conjugate PB-106, PB-119 and PB-120 equivalent hypoglycemic aging test
- mice Male Kunming mice (body weight 24-30 g), the mice were not fasted and banned before the experiment, and were randomly divided into 4 groups, 6 in each group.
- PB-105 10 g/kg
- PB-105 PEGylated (PEG23000) conjugate PB-119 10 g/kg
- PB-105 PEGylated (PEG27000) conjugate PB-120 g/kg.
- the blood glucose level at different time points is the ordinate and the time is the abscissa.
- the aging curve of hypoglycemic effect is established, and the biological half-life and maximum hypoglycemic effect of PB-105 and its PEGylated conjugates are determined. .
- the results are shown in Figure 37.
- PB-105, PB-106, PB-119 and PB-120 all reduced the random blood glucose in mice in a time-dependent manner with biological half-lives of 6.0, 21.7, 24.1 and 26.1 hrs, respectively, with PEG.
- the molecular weight increased and increased; the peak time of hypoglycemic effect was about 1 hour (PB-105) and 4 hours (PB-106, PB-119 and PB-120), respectively.
- PB-106, PB-119 and PB-120 significantly increased PB-105 hypoglycemic effect (3-4 fold increase) with hypoglycemic-time area calculation, and its cumulative effect increased with increasing PEG molecular weight (Fig. 37B).
- the experimental results show that the molecular weight is between 20-27 kDa, and the modification of polyethylene glycol does not reduce the hypoglycemic activity of PB-105, which significantly prolongs the time of hypoglycemic effect and increases the cumulative blood glucose lowering effect.
- Healthy pigeons male or female, are divided into 7 groups of 4-8 each.
- the number of vomiting and the vomiting latency (the time from the administration to the first vomiting).
- the number of vomiting is defined as stretching the neck, opening the mouth, shrugging the shoulders, contracting the abdomen to restore calmness or stopping the vomiting action as one time.
- Example 23 Effects of PB-101, PB-105 and PB-106 on systemic immune allergic reaction and body weight in guinea pigs
- PB-101 and PB-105 are 39 amino acid residues of the polypeptide, which can produce antibodies in vivo after long-term administration (Buse et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in Sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628-2635.
- PB-105 PEGylated (PEG20000) conjugate PB-106 produced a weak negative allergic reaction in guinea pigs.
- PEGylation significantly reduced the immunogenicity of PB-101 or PB-105 and reduced the production of allergic reactions.
- the guinea pigs in the saline group continued to grow during sensitization (the body weight increased by about 38% within 18 days of the experiment).
- the rat body weight was plotted on the ordinate (Fig. 41A).
- the body weight of the saline group continued to increase (the body weight increased by 33.4% within 9 days of the experiment), compared with the saline group.
- the body weight of the rats was decreased by about 5.3% (p ⁇ 0.05) by weight-time AUC.
- the same doses of PB-106, PB-119 and PB were given.
- the body weight of rats was lower than that of PB-105.
- Exenatide can reduce the body weight of obese patients and can cause nausea and vomiting.
- the mechanism of action is related to the inhibition of the feeding center and the stimulating vomiting center in the central nervous system. Larsen. Mechanisms behind GLP-1 induced weight loss, Br J Diabetes Vase Dis 2008 8 (Suppl 2): S34-S41; Schick et al. Glucagonkin peptide 1 (7-36)-specact at lateral and medial hypothalamic sites to suppress feeding in rats.
- mice Male Sprague-Dawley rats (body weight 250-300 g, purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences), were given 30% chloral hydrate (300 mg/kg, ip) anesthesia, large inguinal incision in the right upper margin, separation of femoral arteries and veins, implementation Femoral arteriovenous catheterization (polyethylene PE50 tube, Becton Dickinson, USA), right femoral artery cannula for blood sampling, right femoral vein cannula for drug delivery, PE-50 tube from the back of the neck from the back of the neck, The catheter was filled with heparin solution (200 U/ml), and the incision was sutured.
- heparin solution 200 U/ml
- the rats were reared in a single cage and recovered for more than 12 h.
- the intubated rats were kept freely in the cage and were freely divided into PB-101 group and PB-105 group (3-6 per group), and 5 g/kg were administered to the right femoral vein. 0.08, 0.25, 0.5, 1, 1.5 after administration, respectively Blood was taken through the PE50 tube at 2, 2.5, 3, 4, 5 and 6 hours. Blood samples were prepared by centrifugation on an Eppendorf tube (5000 rpm, 5 min), and -20 C was used. After the plasma samples of each group were prepared, the drug concentration in the samples was measured using an Exenatide EIA Kit (Phoenix Pharmaceuticals, Inc. USA).
- the pharmacokinetic parameters of PB-101 and PB-105 were calculated using the Kinetica 5.0 ( Thermo Fisher Scientific Inc., USA) software for non-compartmental method parameter statistics. 1 , AUC.- ⁇ , t 1/2 , MRT, CL and V ss , etc., the results are shown in Table 4.
- the plasma half-lives of PB-101 and PB-105 were 4.8 ⁇ 0.7 and 4.9 ⁇ 1.4 hrs, respectively (PB-105 vs. PB-101, P >0.05); the area under the drug-time curve was 45.4 ⁇ 1.6 and 47.9 ⁇ , respectively. 19.0 ng*hr/ml (PB-105 vs. PB-101, P > 0.05).
- the experimental results show that PB-105 and PB-101 have similar pharmacokinetic properties.
- Table 4 Pharmacokinetic parameters of PB-101 and PB-105 (3-6 rats per group)
- mice Male Sprague-Dawley rats (body weight 250-300 g, purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences), were given 30% chloral hydrate (300 mg/kg, ip) anesthesia, large inguinal incision in the right upper margin, separation of femoral arteries and veins, implementation Femoral arteriovenous catheterization (polyethylene PE50 tube, Becton Dickinson, USA), right femoral artery cannula for blood sampling, right femoral vein cannula for drug delivery, PE-50 tube from the back of the neck through the back of the neck Out, the catheter was filled with heparin solution (200 U/ml), the incision was sutured, and the rats were reared in a single cage and recovered for more than 12 h.
- heparin solution 200 U/ml
- the intubated rats remained freely active in the cage and were free to eat.
- Blood was collected from the right femoral vein at a dose of 5 g/kg at different time points. Blood was taken through the PE50 tube 48 hours after administration, and blood was taken from the tail vein 48 hours later.
- PB-105 group (0.08, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours after administration), PB-110 group (0.08, 0.25, 0.5, 1 after administration) , 2, 3, 4, 5, 6, 8, 10 hours), group PB-106 (0.08, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72 after administration) , 84, 96 hours), group PB-107 (0.08, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 after administration) , 144 hours), PB-108 and PB-109 groups (0.08, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 after administration) , 132, 156, 168 hours).
- Plasma samples were prepared by centrifugation on an Eppendorf tube (5000 rpm, 5 min), -20. C spare. After the plasma samples of each group were prepared, the drug concentration in the samples was measured using an Exenatide EIA Kit (Phoenix Pharmaceuticals, Inc. USA). The results showed that the plasma concentration value was plotted on the ordinate and the time was on the abscissa. The PEG-conjugated drug-time curve was established. The results showed that PB-105 and its PEGylated conjugate showed rapid distribution and slow elimination ( See Figure 43).
- PB-105 and its PEGylated conjugate were calculated using Kinetica 5.0 (Ther Fisher Scientific Inc., USA) software for non-compartmental method parameter statistics. Max , AUCo-t, AUCo-oo, t 1/2 , MRT, CL and V ss, etc., the results are shown in Table 5. Among them, the plasma half-life of PB-105 is 2.9 ⁇ 0.1 hrs, and the plasma half-life of the PEGylated conjugate is prolonged with the increase of the molecular weight of polyethylene glycol; the area under the PB-105 drug-time curve is 18.2 ⁇ 1.9 ng.
- the Exendin variants of the invention have improved pharmacokinetic properties, significantly lower blood glucose, and have comparable or superior biological activity to Exendin.
- the Exendin variant conjugate which is coupled to the polymer via a cysteine thiol group, significantly prolongs the half-life of the Exendin variant and maintains high biological activity.
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117027747A KR101352225B1 (ko) | 2009-04-23 | 2010-04-23 | 신규한 엑센딘 변형 및 이들의 콘쥬게이트 |
RU2011147083/10A RU2528734C2 (ru) | 2009-04-23 | 2010-04-23 | Новый вариант эксендина и его конъюгат |
US13/265,809 US8575097B2 (en) | 2009-04-23 | 2010-04-23 | Exendin variant and conjugate thereof |
CN2010800180536A CN102421796B (zh) | 2009-04-23 | 2010-04-23 | Exendin变体及其缀合物 |
BRPI1014416-1A BRPI1014416B1 (pt) | 2009-04-23 | 2010-04-23 | Nova variante de exendina e conjugado desta |
EP10766649.7A EP2423223B1 (en) | 2009-04-23 | 2010-04-23 | Novel exendin variant and conjugate thereof |
JP2012506327A JP5937963B2 (ja) | 2009-04-23 | 2010-04-23 | 新規Exendin変異体及びその複合物 |
ZA2011/08484A ZA201108484B (en) | 2009-04-23 | 2011-11-18 | Novel exendin variant and conjugate thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910135363.5 | 2009-04-23 | ||
CN200910135363A CN101870728A (zh) | 2009-04-23 | 2009-04-23 | 新型Exendin变体及其缀合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010121559A1 true WO2010121559A1 (zh) | 2010-10-28 |
Family
ID=42995827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/072094 WO2010121559A1 (zh) | 2009-04-23 | 2010-04-23 | 新型exendin变体及其缀合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8575097B2 (zh) |
EP (1) | EP2423223B1 (zh) |
JP (2) | JP5937963B2 (zh) |
KR (1) | KR101352225B1 (zh) |
CN (2) | CN101870728A (zh) |
BR (1) | BRPI1014416B1 (zh) |
RU (1) | RU2528734C2 (zh) |
WO (1) | WO2010121559A1 (zh) |
ZA (1) | ZA201108484B (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130217622A1 (en) * | 2011-06-28 | 2013-08-22 | B & L Delipharm, Corp. | Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical compostion for preventing or treating diabetes, containing same as active ingredient |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
CN108697768A (zh) * | 2015-12-23 | 2018-10-23 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
US11084879B2 (en) | 2016-04-07 | 2021-08-10 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
WO2023045802A1 (zh) | 2021-09-24 | 2023-03-30 | 派格生物医药(苏州)股份有限公司 | 一种含有聚乙二醇化艾塞那肽变体的药物组合物及其用途 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102690346B (zh) * | 2011-03-22 | 2016-05-25 | 中肽生化有限公司 | 一种治疗糖尿病的多肽及其制备方法和用途 |
CN102718868A (zh) * | 2011-03-30 | 2012-10-10 | 上海华谊生物技术有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
CN103906528A (zh) * | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
CN102617728B (zh) * | 2012-04-13 | 2013-07-03 | 上海交通大学医学院附属瑞金医院 | 一种Exendin-4的18F标记产物的制备方法 |
CN104277104A (zh) * | 2013-07-08 | 2015-01-14 | 派格生物医药(苏州)有限公司 | 包含聚合物和生物活性分子的缀合物及其用途 |
CN104277103A (zh) * | 2013-07-08 | 2015-01-14 | 派格生物医药(苏州)有限公司 | 包含聚合物和生物活性分子的缀合物及其用于减肥的用途 |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
CN104945498B (zh) * | 2014-03-24 | 2018-08-03 | 扬子江药业集团北京海燕药业有限公司 | 长效化PEG-rExendin-4改构体偶联物的制备 |
CN104109201B (zh) * | 2014-04-09 | 2017-11-10 | 江苏省原子医学研究所 | 一种艾塞那肽的18f标记物及制备方法与应用 |
CN104650217B (zh) * | 2015-01-26 | 2018-08-10 | 莎穆(上海)生物科技有限公司 | 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用 |
CN106554403B (zh) | 2015-09-25 | 2021-08-31 | 博瑞生物医药(苏州)股份有限公司 | 艾塞那肽修饰物及其用途 |
CN113456820B (zh) * | 2015-12-29 | 2023-09-08 | 派格生物医药(苏州)股份有限公司 | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 |
CN105936647A (zh) * | 2016-04-27 | 2016-09-14 | 中国药科大学 | 长效化艾塞那肽(Exendin-4)类似物及其应用 |
KR102165920B1 (ko) * | 2018-03-29 | 2020-10-14 | 가톨릭대학교 산학협력단 | 베타 세포 특이적 리간드를 이용한 miRNA 전달용 리포좀 |
CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5539063A (en) | 1991-03-25 | 1996-07-23 | Hoffmann-La Roche Inc. | Polymer for making poly(ethylene glycol)-protein conjugates |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
WO2000041546A2 (en) | 1999-01-14 | 2000-07-20 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist formulations and methods of administration thereof |
WO2000066629A1 (en) | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6455639B1 (en) | 1998-03-24 | 2002-09-24 | Nof Corporation | Oxirane derivative and process for the preparation thereof |
EP1245608A1 (en) | 2001-03-27 | 2002-10-02 | Nof Corporation | Polyethylene glycol and process for producing the same |
WO2003040211A2 (en) | 2001-11-07 | 2003-05-15 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
US6566506B2 (en) | 1993-10-27 | 2003-05-20 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US6858576B1 (en) | 1996-08-08 | 2005-02-22 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
US6864350B2 (en) | 1996-09-26 | 2005-03-08 | Nektar Therapeutics Al, Corporation | Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6872700B1 (en) | 1999-01-14 | 2005-03-29 | Amylin Pharmaceuticals, Inc. | Methods for glucagon suppression |
US6956026B2 (en) | 1997-01-07 | 2005-10-18 | Amylin Pharmaceuticals, Inc. | Use of exendins for the reduction of food intake |
WO2006074600A1 (fr) * | 2005-01-14 | 2006-07-20 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Exendines modifiees et utilisations correspondantes |
WO2006083301A2 (en) | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
WO2007019331A2 (en) * | 2005-08-04 | 2007-02-15 | Nektar Therapeutics Al, Corporation | Conjugates of a g-csf moiety and a polymer |
CN101125207A (zh) | 2006-11-14 | 2008-02-20 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
WO2008076933A2 (en) * | 2006-12-14 | 2008-06-26 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US477967A (en) | 1892-06-28 | Folding bed | ||
US478017A (en) | 1892-06-28 | Mariner s compass | ||
US478425A (en) | 1892-07-05 | Process of generating gas | ||
AU2004231461B2 (en) * | 2003-03-19 | 2009-11-12 | Eli Lilly And Company | Polyethelene glycol linked GLP-1 compounds |
EP2298801A4 (en) * | 2008-06-17 | 2011-08-03 | Otsuka Chemical Co Ltd | GLYCOSYLATED GLP-1 PEPTIDE |
WO2011052523A1 (ja) | 2009-10-30 | 2011-05-05 | 大塚化学株式会社 | 抗原性glp-1アナログの糖鎖付加体 |
-
2009
- 2009-04-23 CN CN200910135363A patent/CN101870728A/zh active Pending
-
2010
- 2010-04-23 JP JP2012506327A patent/JP5937963B2/ja active Active
- 2010-04-23 KR KR1020117027747A patent/KR101352225B1/ko active IP Right Grant
- 2010-04-23 BR BRPI1014416-1A patent/BRPI1014416B1/pt active IP Right Grant
- 2010-04-23 WO PCT/CN2010/072094 patent/WO2010121559A1/zh active Application Filing
- 2010-04-23 RU RU2011147083/10A patent/RU2528734C2/ru active
- 2010-04-23 US US13/265,809 patent/US8575097B2/en active Active
- 2010-04-23 EP EP10766649.7A patent/EP2423223B1/en active Active
- 2010-04-23 CN CN2010800180536A patent/CN102421796B/zh active Active
-
2011
- 2011-11-18 ZA ZA2011/08484A patent/ZA201108484B/en unknown
-
2015
- 2015-02-26 JP JP2015036033A patent/JP2015164916A/ja active Pending
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5539063A (en) | 1991-03-25 | 1996-07-23 | Hoffmann-La Roche Inc. | Polymer for making poly(ethylene glycol)-protein conjugates |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6566506B2 (en) | 1993-10-27 | 2003-05-20 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US7297761B2 (en) | 1996-08-08 | 2007-11-20 | Amylin Pharmaceuticals, Inc. | Pharmaceutical compositions containing exendins |
US6858576B1 (en) | 1996-08-08 | 2005-02-22 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
US6864350B2 (en) | 1996-09-26 | 2005-03-08 | Nektar Therapeutics Al, Corporation | Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6956026B2 (en) | 1997-01-07 | 2005-10-18 | Amylin Pharmaceuticals, Inc. | Use of exendins for the reduction of food intake |
US6455639B1 (en) | 1998-03-24 | 2002-09-24 | Nof Corporation | Oxirane derivative and process for the preparation thereof |
US6872700B1 (en) | 1999-01-14 | 2005-03-29 | Amylin Pharmaceuticals, Inc. | Methods for glucagon suppression |
WO2000041546A2 (en) | 1999-01-14 | 2000-07-20 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist formulations and methods of administration thereof |
US6902744B1 (en) | 1999-01-14 | 2005-06-07 | Amylin Pharmaceuticals, Inc. | Exendin agonist formulations and methods of administration thereof |
WO2000066629A1 (en) | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
CN1372570A (zh) | 1999-04-30 | 2002-10-02 | 安米林药品公司 | 修饰的exendin和exendin激动剂 |
EP1245608A1 (en) | 2001-03-27 | 2002-10-02 | Nof Corporation | Polyethylene glycol and process for producing the same |
WO2003040211A2 (en) | 2001-11-07 | 2003-05-15 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
WO2006083301A2 (en) | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
WO2006074600A1 (fr) * | 2005-01-14 | 2006-07-20 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Exendines modifiees et utilisations correspondantes |
WO2007019331A2 (en) * | 2005-08-04 | 2007-02-15 | Nektar Therapeutics Al, Corporation | Conjugates of a g-csf moiety and a polymer |
CN101125207A (zh) | 2006-11-14 | 2008-02-20 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
WO2008076933A2 (en) * | 2006-12-14 | 2008-06-26 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
Non-Patent Citations (41)
Title |
---|
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO. |
AM. J. PHYSICL ENDOCRINOL. METAB, vol. 281, 2001, pages E242 - 247 |
BAILON ET AL.: "PEG-modified biopharmaceuticals", EXPERT OPIN DELIV., vol. 6, 2009, pages 1 - 16 |
BAILON ET AL.: "Rational design of potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C", BIOCONJUGATE CHEM, vol. 12, 2001, pages 195 - 202 |
BOWEN ET AL.: "Relationship between molecular weight and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein", EXPERIMENTAL HEMATOLOGY, vol. 27, 1999, pages 425 - 32 |
BUSE ET AL.: "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes", DIABETES CARE, vol. 27, 2004, pages 2628 - 2635 |
CUNNINGHAM, B.; WELLS, J., SCIENCE, vol. 244, 1989, pages 1081 - 1085 |
DE VOS, A. ET AL., SCIENCE, vol. 255, 1992, pages 306 - 312 |
DIABETES CARE, vol. 15, 1992, pages 270 - 276 |
DIABETES CARE, vol. 22, 1999, pages 403 - 408 |
DIABETES, vol. 44, 1995, pages 1295 |
DIABETES, vol. 44, 1995, pages 16 - 19 |
DIABETES, vol. 50, 2001, pages 525 - 529 |
DIABETES, vol. 50, 2001, pages 725 |
DIABETES, vol. 51, 2002, pages 1443 - 1452 |
DIABETES, vol. 52, 2003, pages 365 - 371 |
DIABETIC MED, vol. 18, 2001, pages 144 - 149 |
DIABETOLOGIA, vol. 28, 1985, pages 565 - 573 |
DIABETOLOGIA, vol. 45, 2002, pages 1263 - 1273 |
DISBETOLOGIA, vol. 39, 1996, pages 1546 - 1553 |
ENDOER. REV, vol. 16, 1996, pages 390 - 410 |
ENG J. ET AL., J. BIOL. CHEM., vol. 265, 1990, pages 20259 - 62 |
ENG J. ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 7402 - 05 |
ENG, J. ET AL.: "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom.", J. BIOL. CHEM., vol. 267, no. 11, 15 April 1992 (1992-04-15), pages 7402 - 7405, XP001084287 * |
J MED CHEM, vol. 47, 2004, pages 4128 - 4134 |
J. BIOL. CHEM, vol. 265, 1990, pages 20259 - 20262 |
J. BIOL. CHEM, vol. 267, 1992, pages 7402 - 7405 |
J. BIOL. CHEM., vol. 266, 1991, pages 2897 - 2902 |
J. BIOL. CHEM., vol. 266, 1992, pages 21432 - 21437 |
J. CLIN. ENDOCRINOLOGY AND METABOLISM, vol. 88, 2003, pages 3082 - 3089 |
J.R. ROBINSON: "Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC. |
LANCET, vol. 359, 2002, pages 824 - 830 |
LARSEN: "Mechanisms behind GLP-1 induced weight loss", BR J DIABETES VASC DIS, vol. 8, 2008, pages S34 - S41 |
LARSEN: "Mechanisms behind GLP-1 induced weight loss", BR J DIABETES VASC DIS, vol. 8, no. 2, 2008, pages S34 - S41 |
NAT. BIOTECH, vol. 23, 2005, pages 857 - 861 |
NATURE, vol. 379, 1996, pages 69 - 72 |
RECENT PROG. HORMNE RES., vol. 56, 2001, pages 377 - 399 |
SCHICK ET AL.: "Glucagon like peptide 1 (7-36)-amide acts at lateral and medial hypothalamic sites to suppress feeding in rats", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, vol. 284, 2003, pages R1427 - 35 |
SCHICK ET AL.: "Glucagonlike peptide 1 (7-36)-amide acts at lateral and medial hypothalamic sites to suppress feeding in rats", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, vol. 284, 2003, pages R1427 - 35 |
See also references of EP2423223A4 |
SMITH, L. ET AL., J.MOL.BIOL., vol. 224, 1992, pages 899 - 904 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103338790B (zh) * | 2011-06-28 | 2018-01-23 | Theraly 制药公司 | 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物 |
CN103338790A (zh) * | 2011-06-28 | 2013-10-02 | B&L德利药物株式会社 | 用聚乙二醇或其衍生物聚乙二醇化的唾液素-4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物 |
JP2014520798A (ja) * | 2011-06-28 | 2014-08-25 | ビーアンドエル デリファーム, コーポレイション | ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物 |
US20130217622A1 (en) * | 2011-06-28 | 2013-08-22 | B & L Delipharm, Corp. | Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical compostion for preventing or treating diabetes, containing same as active ingredient |
US10406230B2 (en) | 2011-06-28 | 2019-09-10 | D&D Pharmatech Inc. | Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US10253079B2 (en) | 2012-12-21 | 2019-04-09 | Sanofi | Functionalized Exendin-4 derivatives |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US9745360B2 (en) | 2012-12-21 | 2017-08-29 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
CN108697768A (zh) * | 2015-12-23 | 2018-10-23 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
US11123405B2 (en) | 2015-12-23 | 2021-09-21 | The Johns Hopkins University | Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
US11084879B2 (en) | 2016-04-07 | 2021-08-10 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
WO2023045802A1 (zh) | 2021-09-24 | 2023-03-30 | 派格生物医药(苏州)股份有限公司 | 一种含有聚乙二醇化艾塞那肽变体的药物组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
US8575097B2 (en) | 2013-11-05 |
RU2528734C2 (ru) | 2014-09-20 |
EP2423223A4 (en) | 2012-11-28 |
RU2011147083A (ru) | 2013-05-27 |
BRPI1014416B1 (pt) | 2021-11-23 |
BRPI1014416A2 (pt) | 2020-08-18 |
ZA201108484B (en) | 2013-01-30 |
US20120196795A1 (en) | 2012-08-02 |
CN102421796A (zh) | 2012-04-18 |
EP2423223A1 (en) | 2012-02-29 |
KR20120024626A (ko) | 2012-03-14 |
EP2423223B1 (en) | 2015-04-15 |
CN101870728A (zh) | 2010-10-27 |
JP2012524730A (ja) | 2012-10-18 |
KR101352225B1 (ko) | 2014-01-15 |
JP2015164916A (ja) | 2015-09-17 |
JP5937963B2 (ja) | 2016-06-22 |
CN102421796B (zh) | 2013-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010121559A1 (zh) | 新型exendin变体及其缀合物 | |
RU2593774C2 (ru) | Пролекарства, содержащие конъюгат эксендин-линкер | |
EP1605897B1 (en) | Polyethelene glycol link glp-1 compounds | |
US9265723B2 (en) | Long acting insulin composition | |
US10806797B2 (en) | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate | |
JP2006520818A5 (zh) | ||
KR20210062053A (ko) | GLP1-Fc 융합 단백질 및 이의 접합체 | |
CN105985425B (zh) | 一种聚乙二醇修饰的exendin类似物及其制备方法和应用 | |
KR20070115602A (ko) | 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도 | |
JP5706331B2 (ja) | 部位特異的にモノ抱合化されたインスリン分泌性のglp−1ペプチド | |
EA044650B1 (ru) | Слитый белок glp1-fc и его конъюгат |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080018053.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10766649 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13265809 Country of ref document: US Ref document number: 2012506327 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4542/KOLNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117027747 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010766649 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011147083 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1014416 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1014416 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111021 |